[vc_row][vc_column][vc_column_text] After a well-documented lull in 2016 and a sluggish start to 2017, the global therapeutic IPO market has started to bounce back in Q2, […]
[vc_row][vc_column][vc_column_text] Healthcare multinational Johnson & Johnson will pay $30B to acquire Swiss drugmaker Actelion in an all-cash deal. Under the conditions of the deal, Actelion will […]